Skip to main content
CARM logo

Carisma Therapeutics, Inc. (CARM) Stock Price & Analysis

Carisma Therapeutics, Inc. (CARM) — price $0.0003 (+50.00%), as of the Nov 18, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$0.0003 +$0.0001 (+50.00%)

Carisma Therapeutics, Inc. · CARM

Carisma Therapeutics, Inc. is a biopharmaceutical company focused on developing CAR-macrophage therapies for solid tumors. Their innovative approach leverages macrophage biology and CAR engineering to enhance the immune response against cancer.

Price as of Nov 18, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • RLYB · Rallybio Corporation · 82 /100
  • ICCC · ImmuCell Corporation · 82 /100
  • ORMP · Oramed Pharmaceuticals Inc. · 72 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.0003
Change on the day+50.00%
52-week range$0.0001 – $0.10
Price / earnings (trailing)0.00
Shares traded on the day10.3K

Price & events

Other perspectives

Council score for Carisma Therapeutics (CARM): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Moderate
Revenue Growth Strong
Gross Margin Moderate

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Carisma Therapeutics (CARM), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Carisma Therapeutics, Inc. (CARM) is the company analyzed here. It employs 46 people and is led by Craig R. Jalbert. In Q3 FY2025 it reported revenue of $45M and net income of $45M.

2 · Latest results

What do the latest results show for Carisma Therapeutics (CARM)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $45M. Against analyst estimates the company has EPS beat 3 of the last 8 reports.

Quarterly income statement — 3 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$45M$45M$1.07 (diluted)
Q1 FY2025$4M-$9M-$0.22 (diluted)
Q4 FY2024$4M-$18M-$0.42 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Carisma Therapeutics (CARM)?

Short answer · as of

The distress and quality screens read Altman Z -45.90 · Piotroski F 3. Trailing ratios: current ratio 0.86.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -45.90 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 8 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Carisma Therapeutics (CARM)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $9.11M · EPS -0.52 · 1 analysts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • The newest quarter held here (Q3 FY2025) was filed Nov 12, 2025 — 6 months ago.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$9.11M
EPS estimate
$-0.52

Measured against a quoted price of $0.0003 (as of Nov 18, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held CARM in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported CARM in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What Investors Ask About Carisma Therapeutics (CARM)

These answers are editorial: 1 of these 1 answer is drawn from the CARM research dossier (written Jun 1, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.

What do analysts say about CARM stock?

Analyst coverage of Carisma Therapeutics, Inc. is limited due to its OTC listing and early stage of development. However, analysts generally view the company's CAR-macrophage technology as promising, given its potential to address unmet needs in solid tumor treatment.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Jun 1, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 8 from Financial Modeling Prep (FMP) and 9 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.